Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NC100150

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
The purpose of this study was to determine the cellular distribution and degradation in rat liver following intravenous injection… Expand
  • figure 1
  • figure 2
  • figure 5
  • figure 3
  • figure 4
2004
2004
To investigate the duration of liver R2* enhancement and pharmacokinetics following administration of an iron oxide nanoparticle… Expand
Highly Cited
2003
Highly Cited
2003
To investigate the physiological origins responsible for the varying blood oxygenation level dependent (BOLD) magnetic resonance… Expand
2003
2003
To assess the feasibility of Clariscan™, an intravascular contrast agent, for free breathing, navigator assisted, high resolution… Expand
Highly Cited
2001
Highly Cited
2001
PURPOSE To define the diagnostic potential of magnetic resonance (MR) imaging enhanced with ultrasmall superparamagnetic iron… Expand
Highly Cited
2000
Highly Cited
2000
A preparation of monocrystalline iron oxide nanoparticles with an oxidized starch coating, currently in clinical trials (NC100150… Expand
2000
2000
The influence of increasing doses of NC100150 Injection (Clariscan™) and echo times on visualization of pulmonary vessels and… Expand
Highly Cited
1999
Highly Cited
1999
In this Phase I clinical study, a novel ultrasmall superparamagnetic iron oxide contrast agent, NC100150 Injection (Nycomed… Expand
1999
1999
A new ultrasmall superparamagnetic iron oxide (Clariscan; NC100150 Injection) was studied in domestic farm pigs. The T1 effects… Expand
1999
1999
Recent developments of novel magnetic resonance intravascular contrast agents with low T1 in blood and a long intravascular half… Expand
  • figure 1
  • figure 2
  • table I
  • table 2